|
|
|
|
|
|
The Public TV program " Curious" profiled a patient who was being treated with an experimental drug in a clinical trial at City of Hope. You can find out more information about the trial here. You will also find links to Web sites that allow you to search for all open clinical trials being conducted at City of Hope and across the U.S.
If you need any additional information about the IT-101 clinical trial conducted at City of Hope after reading the Q&A, you can send us an email, and we will respond as soon as we can. Thank you.
|
|
IT-101 is an experimental drug, developed by Calando Pharmaceuticals, that acts as a targeted chemotherapy. The drug uses the cancer-killing compound camptothecin, which is engineered into a nanoparticle to attack cancer cells but leave healthy tissue alone.
Researchers are investigating how effective the drug is against tumors and if it can lessen the severity of side effects common to chemotherapy such as nausea, vomiting, hair loss and fatigue. You can find more detailed information about the compound itself on the Calando Pharmaceuticals Web site. IT-101 is an experimental drug currently in an early stage clinical trials. Only patients enrolled in clinical trials can receive treatment with IT-101.
The Phase I clinical trial of IT-101 is currently closed to enrollment. A Phase II clinical trial to study IT-101 in hematological cancers such as lymphoma and leukemia is in development.
In order to potentially participate in any clinical trial at City of Hope, including IT-101, you must first register as a patient with New Patient Services and be evaluated by our doctors. Evaluations cannot be conducted over the phone or by email. To become a patient, please click here or call New Patient Services at 800-826-HOPE (4673).
All potential new drugs must undergo three phases of clinical trials and be reviewed by the U.S. Food and Drug Administration before they can be approved for general use. Each phase of testing can potentially take years to complete. The Phase I clinical trial of IT-101 is currently closed to enrollment. A Phase II clinical trial to study IT-101 in hematological cancers such as lymphoma and leukemia is in development.
In order to potentially participate in any clinical trial at City of Hope, including IT-101, you must first register as a patient with New Patient Services and be evaluated by our doctors. Evaluations cannot be conducted over the phone or by email. To become a patient, please click here or call New Patient Services at 800-826-HOPE (4673).
Additional information can be found on the City of Hope Clinical Trials Web site. Yes. You can request a referral from your doctor, or you can contact City of Hope's New Patient Services online or call (800) 826-HOPE (4673) to initiate the process. Calando Pharmaceuticals is conducting Phase II trials at various Calando Pharmaceuticals sites. When available, these trials will be listed at various web sites including the US clinical trial site and at the Calando Pharmaceuticals website. You can visit the City of Hope Clinical Trials Web site ( http://clinicaltrials.coh.org/) to search for other open clinical trials for which you may be eligible. You can also visit ClinicalTrials.gov ( http://www.clinicaltrials.gov/) to search for other cancer clinical trials being conducted throughout the U.S. Chemotherapy drugs interrupt the process of cell division and replication, which cancer cells do in an uncontrolled manner. Unfortunately, healthy cells also regularly carry out the same process of duplication, and standard chemotherapy kills both healthy and cancerous cells without distinction.
IT-101 uses the cancer-killing compound camptothecin, which is engineered into nanoparticles to attack cancer cells but leave healthy tissue alone. With less damage to healthy cells, the compound has the potential to lessen the severity of side effects common to chemotherapy such as nausea, vomiting, hair loss and fatigue. City of Hope's Phase I clinical trial of IT-101 tested dosage and safety against advanced solid tumors in patients with all cancers, including ovarian cancer, lung cancer, and pancreatic cancer. The Phase I trial is currently closed to enrollment.
A Phase II trial is in development for hematological cancers. Other centers are running IT-101 trials in different cancers. You can visit the Calando Pharmaceuticals web site for more information or search clinicaltrials.gov for ongoing IT-101 clinical trials around the country. Your insurance company has to approve the course of treatment to ensure reimbursement. |
|
|
UPDATE:
The Phase I clinical trial of IT-101 is currently closed to enrollment. A Phase II clinical trial to study IT-101 in hematological cancers such as lymphoma and leukemia is in development.
If you are interested in enrolling in the Phase II clinical trial, when it opens, you will need to be evaluated in person by our doctors, who can then determine your eligibility for IT-101 or any other clinical trial being conducted at City of Hope. Evaluations can be scheduled only after the Phase II trial is open.
In order to potentially participate in any clinical trial at City of Hope, including IT-101, you must first register as a patient with New Patient Services and be evaluated by our doctors. Evaluations cannot be conducted over the phone or by email
|
|
|
|
|
 To make an appointment for yourself, a family member or a friend, please complete and submit our Become a Patient Request Form, or call City of Hope at 800-826-HOPE (4673). |
|
|